- Home
- FENC vs DERM Comparison
FENC vs DERM Comparison
Compare FENC & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- DERM
- Stock Information
- Founded
- FENC 1996
- DERM 2014
- Country
- FENC United States
- DERM United States
- Employees
- FENC N/A
- DERM N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- DERM Biotechnology: Pharmaceutical Preparations
- Sector
- FENC Health Care
- DERM Health Care
- Exchange
- FENC Nasdaq
- DERM Nasdaq
- Market Cap
- FENC 156.9M
- DERM 174.7M
- IPO Year
- FENC 2001
- DERM 2021
- Fundamental
- Price
- FENC $5.95
- DERM $6.88
- Analyst Decision
- FENC Strong Buy
- DERM Strong Buy
- Analyst Count
- FENC 2
- DERM 2
- Target Price
- FENC $14.00
- DERM $10.00
- AVG Volume (30 Days)
- FENC 50.4K
- DERM 78.2K
- Earning Date
- FENC 05-20-2025
- DERM 05-20-2025
- Dividend Yield
- FENC N/A
- DERM N/A
- EPS Growth
- FENC N/A
- DERM N/A
- EPS
- FENC N/A
- DERM N/A
- Revenue
- FENC $47,538,000.00
- DERM $56,134,000.00
- Revenue This Year
- FENC $2.68
- DERM $29.83
- Revenue Next Year
- FENC $71.63
- DERM $54.88
- P/E Ratio
- FENC N/A
- DERM N/A
- Revenue Growth
- FENC 123.69
- DERM N/A
- 52 Week Low
- FENC $3.96
- DERM $3.20
- 52 Week High
- FENC $10.07
- DERM $7.84
- Technical
- Relative Strength Index (RSI)
- FENC 51.33
- DERM 52.73
- Support Level
- FENC $5.85
- DERM $6.47
- Resistance Level
- FENC $6.61
- DERM $7.15
- Average True Range (ATR)
- FENC 0.36
- DERM 0.49
- MACD
- FENC 0.06
- DERM -0.09
- Stochastic Oscillator
- FENC 54.20
- DERM 37.25
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.